Sosei doses first patient with experimental neurodegenerative drug
Sosei has announced that the first healthy subject has been dosed with HTL0014242 – a novel small molecule being tested for its ability to slow neurodegeneration.
Read More
Tag: mGlu5 negative allosteric modulator
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
